Retraction Note: Suppression of the xCT–CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin (Breast Cancer Res Treat, 147, 203-210, (2014), DOI 10.1007/s10549-014-3068-6);Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 203-210

  Wang, Feng ^a   Yang, Yong ^b  

^a TONGJI UNIVERSITY   (China)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Chemotherapy; Reactive oxygen; Species; Triple negative breast cancer; xCT CD44v antiporter system

Indexed keywords

ANTIPORTER; CD44V ANTIGEN; CYSTEINE; DOXORUBICIN; GLUTATHIONE; LENTIVIRUS VECTOR; PROTEIN XCT; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTINEOPLASTIC ANTIBIOTIC; HERMES ANTIGEN; SLC7A11 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; UPREGULATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; RETRACTED ARTICLE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

AMINO ACID TRANSPORT SYSTEM Y+; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD44; BLOTTING, WESTERN; CELL PROLIFERATION; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84906056781     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3399-y     Document Type: Erratum

References (26)

1. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8(3):235-244. doi:10.1016/S1470-2045(07)70074- 8
2. Duffy MJ, McGowan PM, Crown J (2012) Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 131(11):2471-2477. doi:10.1002/ijc.27632
3. Weigelt B, Reis JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718-730. doi:10.1038/nrclinonc.2009.166
4. Isakoff SJ (2010) Triple-negative breast cancer role of specific chemotherapy agents. Cancer J 16(1):53-61. doi:10.1097/PPO.0b013e3181d24ff7
5. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA (2008) Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol 72(2):474-484. doi:10.1016/j.ijrobp.2008.01.039
6. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S (2012) Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 23(9):2223-2234. doi:10.1093/annonc/mds067
7. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van't Veer LJ, Polyak K, McCormick F, Gray JW (2013) Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24(4):450-465. doi:10.1016/j.ccr. 2013.08.020
8. Lo M, Ling V, Wang YZ, Gout PW (2008) The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99(3):464-472. doi:10.1038/sj.bjc.6604485
9. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591. doi:10.1038/nrd2803
10. Nagano O, Okazaki S, Saya H (2013) Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32(44):5191-5198. doi:10.1038/onc.2012. 638
11. Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H (1995) Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 60(4):471-477. doi:10.1002/ijc.2910600408
12. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387-400. doi:10.1016/j.ccr.2011.01.038
13. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O (2013) xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73(6):1855-1866. doi:10.1158/0008-5472.CAN- 12-3609-T
14. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R (1999) 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59(4):862-867
15. Wang J, Yi J (2008) Cancer cell killing via ROS To increase or decrease, that is the question. Cancer Biol Ther 7(12):1875-1884. doi:10.4161/cbt.7.12. 7067
16. Velimezi G, Liontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M, Dereli-Oz A, Kocylowski M, Pateras IS, Evangelou K, Kotsinas A, Orsolic I, Bursac S, Cokaric-Brdovcak M, Zoumpourlis V, Kletsas D, Papafotiou G, Klinakis A, Volarevic S, Gu W, Bartek J, Halazonetis TD, Gorgoulis VG (2013) Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol 15(8):967-977. doi:10.1038/ncb2795
17. Yang Y, Wolfram J, Shen J, Zhao Y, Fang X, Shen H, Ferrari M (2013) Live-cell single-molecule imaging reveals clathrin and caveolin-1 dependent docking of SMAD4 at the cell membrane. FEBS Lett 587(24):3912-3920. doi:10.1016/j.febslet.2013.10.041
18. Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493(7433):542-546. doi:10.1038/nature11743
19. Shih AY, Murphy TH (2001) xCT cystine transporter expression in HEK293 cells: pharmacology and location. Biochem Biophys Res Commun 282(5):1132-1137. doi:10.1006/bbrc.2001.4703
20. Yang Y, Wolfram J, Fang X, Shen H, Ferrari M (2014) Polyarginine induces an antitumor immune response through binding to toll-Like receptor 4. Small 10(7):1250-1254. doi:10.1002/smll.201302887
21. Pastore A, Piemonte F, Locatelli M, Lo Russo A, Gaeta LM, Tozzi G, Federici G (2001) Determination of blood total, reduced, and oxidized glutathione in pediatric subjects. Clin Chem 47(8):1467-1469
22. O'Shaughnessy JA, Fisherman JS, Cowan KH (1994) Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 21(5 Suppl 8):19-23
23. Kim SY, Kim SJ, Kim BJ, Rah SY, Chung SM, Im MJ, Kim UH (2006) Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 38(5):535-545. doi:10.1038/emm.2006.63
24. 2- and p53-dependent pathways. J Biol Chem 279(24):25535-25543. doi:10.1074/jbc. M400944200
25. Gilliam LA, Moylan JS, Patterson EW, Smith JD, Wilson AS, Rabbani Z, Reid MB (2012) Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am J Physiol Cell Physiol 302(1):C195-C202. doi:10.1152/ajpcell. 00217.2011
26. Engel RH, Evens AM (2006) Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11:300-312. doi:10.2741/1798